Nikkei 225
38.294,79 +220,81 (+0,58%) Dow Jones 30
39.387,76 +331,36 (+0,85%) Bitcoin EUR
58.282,06 +1.254,75 (+2,20%) CMC Crypto 200
1.351,88 +51,78 (+3,98%) Nasdaq Compositive
16.346,26 +43,46 (+0,27%) S&P 500
5.214,08 +26,41 (+0,51%)
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc.
601 Genome Way
Suite 2001
Huntsville, AL 35806
United States
256 327 0566
https://serinatherapeutics.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Beschreibung
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama.
Corporate Governance
Serina Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.
